Nyxoah SA
Business
Nyxoah SA is a medical technology company focused on developing and commercializing innovative solutions to treat obstructive sleep apnea (OSA) using hypoglossal nerve stimulation therapies. Its main product is the Genio system, a CE‑marked, minimally invasive, battery‑free, leadless bilateral hypoglossal neurostimulator complemented by external activation chips, disposable patches, chargers and clinical support services. Its business is organized around clinical development, regulatory affairs, manufacturing and commercial sales and marketing, supported by ongoing trials, R&D and strategic partnerships. Nyxoah targets European markets with country‑specific reimbursement strategies, is pursuing U.S. marketing authorization, and distributes primarily via direct sales to ENTs, sleep doctors, hospitals and specialized centers.
Summary from filing dated 2025-03-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-90.08M |
| Total assets | $118.50M |
| Total liabilities | $69.34M |
| Stockholders' equity | — |
| Operating cash flow | — |